RT Journal Article
T1 Eculizumab-related progressive multifocal leukoencephalopathy
A1 Gómez Cibera, Emilio
A1 Ivanovic Barbeito, Yerko
A1 Gutiérrez Martínez, Eduardo
A1 Morales Ruiz, Enrique
A1 Abradelo De Usera, Manuel
A1 Hilario Barrio, Amaya
A1 Ramos González, Ana
A1 Ruíz Morales, Juan
A1 Villarejo Galende, Alberto
AB Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the CNS caused by reactivation of the polyomavirus JC (JCV). In the context of immunosuppression, JCV can reactivate and spread to brain infecting oligodendrocytes. Eculizumab is a first-in-class humanized monoclonal antibody developed to target the cleavage of C5, preventing the release of C5a and activation of the terminal complement pathway. It has been shown to be effective in the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS). Eculizumab can impair neutro- phil and monocyte functions and predispose to encapsulated bacteria infections. We report the novel finding of PML in a patient receiving eculizumab.
PB Wolters Kluwer
YR 2015
FD 2015-12-30
LK https://hdl.handle.net/20.500.14352/115594
UL https://hdl.handle.net/20.500.14352/115594
LA eng
NO Gómez-Cibeira E, Ivanovic-Barbeito Y, Gutiérrez-Martínez E, Morales E, Abradelo M, Hilario A, Ramos A, Ruiz-Morales J, Villarejo-Galende A. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology. 2016 Jan 26;86(4):399-400. doi: 10.1212/WNL.0000000000002312. Epub 2015 Dec 30. PMID: 26718572; PMCID: PMC4776092.
DS Docta Complutense
RD 10 abr 2025